Literature DB >> 35962572

A proof of concept using the Ussing chamber methodology to study pediatric intestinal drug transport and age-dependent differences in absorption.

Eva J Streekstra1,2, Márton Kiss1, Jeroen van den Heuvel1, Johan Nicolaï3, Petra van den Broek1, Sanne M B I Botden4, Martijn W J Stommel5, Lara van Rijssel1, Anna-Lena Ungell3, Evita van de Steeg2, Frans G M Russel1, Saskia N de Wildt1,6.   

Abstract

Little is known about the impact of age on the processes governing human intestinal drug absorption. The Ussing chamber is a system to study drug transport across tissue barriers, but it has not been used to study drug absorption processes in children. This study aimed to explore the feasibility of the Ussing chamber methodology to assess pediatric intestinal drug absorption. Furthermore, differences between intestinal drug transport processes of children and adults were explored as well as the possible impact of age. Fresh terminal ileal leftover tissues from both children and adults were collected during surgery and prepared for Ussing chamber experiments. Paracellular (enalaprilat), transcellular (propranolol), and carrier-mediated drug transport by MDR1 (talinolol) and BCRP (rosuvastatin) were determined with the Ussing chamber methodology. We calculated apparent permeability coefficients and efflux ratios and explored their relationship with postnatal age. The success rate for the Ussing chamber experiments, as determined by electrophysiological measurements, was similar between children (58%, N = 15, median age: 44 weeks; range 8 weeks to 17 years) and adults (67%, N = 13). Mean serosal to mucosal transport of talinolol by MDR1 and rosuvastatin by BCRP was higher in adult than in pediatric tissues (p = 0.0005 and p = 0.0091). In contrast, within our pediatric cohort, there was no clear correlation for efflux transport across different ages. In conclusion, the Ussing chamber is a suitable model to explore pediatric intestinal drug absorption and can be used to further elucidate ontogeny of individual intestinal pharmacokinetic processes like drug metabolism and transport.
© 2022 The Authors. Clinical and Translational Science published by Wiley Periodicals LLC on behalf of American Society for Clinical Pharmacology and Therapeutics.

Entities:  

Mesh:

Substances:

Year:  2022        PMID: 35962572      PMCID: PMC9579398          DOI: 10.1111/cts.13368

Source DB:  PubMed          Journal:  Clin Transl Sci        ISSN: 1752-8054            Impact factor:   4.438


  38 in total

1.  Permeation of four oral drugs through human intestinal mucosa.

Authors:  Erina Pretorius; Patrick J D Bouic
Journal:  AAPS PharmSciTech       Date:  2009-03-12       Impact factor: 3.246

2.  Differential expression of ABC transporters (MDR1, MRP1, BCRP) in developing human embryos.

Authors:  A Konieczna; B Erdösová; R Lichnovská; M Jandl; K Cížková; J Ehrmann
Journal:  J Mol Histol       Date:  2011-10-20       Impact factor: 2.611

3.  ATP-dependent transport of rosuvastatin in membrane vesicles expressing breast cancer resistance protein.

Authors:  Liyue Huang; Yi Wang; Scott Grimm
Journal:  Drug Metab Dispos       Date:  2006-01-13       Impact factor: 3.922

Review 4.  The P-glycoprotein multidrug transporter.

Authors:  O Fardel; V Lecureur; A Guillouzo
Journal:  Gen Pharmacol       Date:  1996-12

5.  Regional Intestinal Permeability in Rats: A Comparison of Methods.

Authors:  Carl Roos; David Dahlgren; Erik Sjögren; Christer Tannergren; Bertil Abrahamsson; Hans Lennernäs
Journal:  Mol Pharm       Date:  2017-10-05       Impact factor: 4.939

6.  Use of Body Surface Area for Dosing of Vancomycin.

Authors:  Elizabeth L Sawrey; Mary W Subramanian; Kacy A Ramirez; Brandy S Snyder; Brittany B Logston; Gregory B Russell
Journal:  J Pediatr Pharmacol Ther       Date:  2019 Jul-Aug

7.  Suitability of enalapril as a probe of the dipeptide transporter system: in vitro and in vivo studies.

Authors:  R A Morrison; S Chong; A M Marino; M A Wasserman; P Timmins; V A Moore; W J Irwin
Journal:  Pharm Res       Date:  1996-07       Impact factor: 4.200

Review 8.  Post-translational modifications of transporters.

Authors:  Lindsay C Czuba; Kathleen M Hillgren; Peter W Swaan
Journal:  Pharmacol Ther       Date:  2018-06-30       Impact factor: 12.310

Review 9.  Preference for pharmaceutical formulation and treatment process attributes.

Authors:  Katie D Stewart; Joseph A Johnston; Louis S Matza; Sarah E Curtis; Henry A Havel; Stephanie A Sweetana; Heather L Gelhorn
Journal:  Patient Prefer Adherence       Date:  2016-07-27       Impact factor: 2.711

10.  Comprehensive analysis of normal adjacent to tumor transcriptomes.

Authors:  Dvir Aran; Roman Camarda; Justin Odegaard; Hyojung Paik; Boris Oskotsky; Gregor Krings; Andrei Goga; Marina Sirota; Atul J Butte
Journal:  Nat Commun       Date:  2017-10-20       Impact factor: 14.919

View more
  1 in total

1.  A proof of concept using the Ussing chamber methodology to study pediatric intestinal drug transport and age-dependent differences in absorption.

Authors:  Eva J Streekstra; Márton Kiss; Jeroen van den Heuvel; Johan Nicolaï; Petra van den Broek; Sanne M B I Botden; Martijn W J Stommel; Lara van Rijssel; Anna-Lena Ungell; Evita van de Steeg; Frans G M Russel; Saskia N de Wildt
Journal:  Clin Transl Sci       Date:  2022-08-12       Impact factor: 4.438

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.